Predictive role of host constitutive variants in neoadjuvant therapy of esophageal cancer

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Chemoradiotherapy followed by surgery is at present the standard therapeutic approach for esophageal cancer (EC) in patients with resectable tumor. However, response to neoadjuvant therapy is characterized by a strong interpatient variability, and the identification of markers predictive of outcome is mandatory. In this review, taking into account the currently available literature, we report the impact that host genetic variables can have on EC neoadjuvant therapy. We mainly focused on the gene variants involved in the pharmacokinetics and pharmacodynamics of the common chemotherapeutic drugs used to treat EC patients, commented on the weakness of the present knowledge, and discussed the future strategies to achieve a more personalized and effective EC treatment.

Original languageEnglish
Pages (from-to)805-820
Number of pages16
JournalPharmacogenomics
Volume17
Issue number7
DOIs
Publication statusPublished - May 1 2016

Fingerprint

Neoadjuvant Therapy
Esophageal Neoplasms
Chemoradiotherapy
Pharmacokinetics
Therapeutics
Pharmaceutical Preparations
Genes
Neoplasms

Keywords

  • esophageal cancer
  • neoadjuvant chemotherapy
  • pharmacogenetics
  • polymorphism
  • predictive marker
  • therapy outcome

ASJC Scopus subject areas

  • Pharmacology
  • Genetics
  • Molecular Medicine

Cite this

Predictive role of host constitutive variants in neoadjuvant therapy of esophageal cancer. / Rumiato, Enrica; Boldrin, Elisa; Amadori, Alberto; Saggioro, Daniela.

In: Pharmacogenomics, Vol. 17, No. 7, 01.05.2016, p. 805-820.

Research output: Contribution to journalReview article

@article{7caf018b6f8a46f8b0d315204601967b,
title = "Predictive role of host constitutive variants in neoadjuvant therapy of esophageal cancer",
abstract = "Chemoradiotherapy followed by surgery is at present the standard therapeutic approach for esophageal cancer (EC) in patients with resectable tumor. However, response to neoadjuvant therapy is characterized by a strong interpatient variability, and the identification of markers predictive of outcome is mandatory. In this review, taking into account the currently available literature, we report the impact that host genetic variables can have on EC neoadjuvant therapy. We mainly focused on the gene variants involved in the pharmacokinetics and pharmacodynamics of the common chemotherapeutic drugs used to treat EC patients, commented on the weakness of the present knowledge, and discussed the future strategies to achieve a more personalized and effective EC treatment.",
keywords = "esophageal cancer, neoadjuvant chemotherapy, pharmacogenetics, polymorphism, predictive marker, therapy outcome",
author = "Enrica Rumiato and Elisa Boldrin and Alberto Amadori and Daniela Saggioro",
year = "2016",
month = "5",
day = "1",
doi = "10.2217/pgs-2016-0009",
language = "English",
volume = "17",
pages = "805--820",
journal = "Pharmacogenomics",
issn = "1462-2416",
publisher = "Future Medicine Ltd.",
number = "7",

}

TY - JOUR

T1 - Predictive role of host constitutive variants in neoadjuvant therapy of esophageal cancer

AU - Rumiato, Enrica

AU - Boldrin, Elisa

AU - Amadori, Alberto

AU - Saggioro, Daniela

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Chemoradiotherapy followed by surgery is at present the standard therapeutic approach for esophageal cancer (EC) in patients with resectable tumor. However, response to neoadjuvant therapy is characterized by a strong interpatient variability, and the identification of markers predictive of outcome is mandatory. In this review, taking into account the currently available literature, we report the impact that host genetic variables can have on EC neoadjuvant therapy. We mainly focused on the gene variants involved in the pharmacokinetics and pharmacodynamics of the common chemotherapeutic drugs used to treat EC patients, commented on the weakness of the present knowledge, and discussed the future strategies to achieve a more personalized and effective EC treatment.

AB - Chemoradiotherapy followed by surgery is at present the standard therapeutic approach for esophageal cancer (EC) in patients with resectable tumor. However, response to neoadjuvant therapy is characterized by a strong interpatient variability, and the identification of markers predictive of outcome is mandatory. In this review, taking into account the currently available literature, we report the impact that host genetic variables can have on EC neoadjuvant therapy. We mainly focused on the gene variants involved in the pharmacokinetics and pharmacodynamics of the common chemotherapeutic drugs used to treat EC patients, commented on the weakness of the present knowledge, and discussed the future strategies to achieve a more personalized and effective EC treatment.

KW - esophageal cancer

KW - neoadjuvant chemotherapy

KW - pharmacogenetics

KW - polymorphism

KW - predictive marker

KW - therapy outcome

UR - http://www.scopus.com/inward/record.url?scp=84973579545&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973579545&partnerID=8YFLogxK

U2 - 10.2217/pgs-2016-0009

DO - 10.2217/pgs-2016-0009

M3 - Review article

VL - 17

SP - 805

EP - 820

JO - Pharmacogenomics

JF - Pharmacogenomics

SN - 1462-2416

IS - 7

ER -